妙可藍多(600882.SH):5%以上股東王永香集中競價減持204.49萬股
格隆匯5月19日丨妙可藍多(600882.SH)公佈,截至本公告披露日,公司5%以上股東王永香持有公司無限售流通股1842.25萬股,佔公司股份總數的4.50%。
公司於2020年1月18日發佈了《持股5%以上股東減持股份計劃公告》,王永香計劃減持公司股份不超過1227萬股,即不超過公司總股本的3.00%,其中擬以集中競價交易方式減持公司股份合計不超過409萬股,擬以大宗交易方式減持公司股份合計不超過818萬股。
2020年2月18日至2020年5月19日,集中競價交易減持數量過半,王永香通過集中競價交易方式減持公司股份204.49萬股,佔公司股份總數的0.50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.